Bedaquiline is a diarylquinoline antimycobacterial drug prescribed for the treatment of Multidrug-Resistant Tuberculosis (MDR-TB). It targets the energy metabolism of the bacteria by inhibiting the proton pump of mycobacterial ATP...

No abstract

No abstract

Antibiotics are robust medicines that are widely used from centuries together to treat bacterial infections such as UTI, Typhoid, and Cholera etc. The similarity between viral and bacterial infection has resulted in the misuse of these antibiotics, the result of which is the development of resistant strains. Such indiscriminate drug usage has been increasing in a vulnerable geriatric and pediatric population. The increase in per capita health expenditure has enhanced the global market of these class of drugs, and the scope is likely to shoot up in the coming years, paving the way for young investors to emerging. The Global market for antibiotics is highly competitive and has a large number of significant players dominating the market share. During the forecast period experts in the field have evaluated and segment to dominate in LAMEA (Latin America, Middle East and Africa) holding the majority of the Market share. However, Asia Pacific was found to be the highest region for contributing more revenues. Detailed market analysis for / was conducted by doing secondary research where the market segments were compared for antibiotics. The paper discusses several issues related to the area of medicines.